MEDLEM · Cost-effective microfluidic electronic devices for optimal drug administration based on fractional pharmacokinetics for leukemia treatments
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2016-01-01 → 2019-12-31
- Финансиране от ЕС
- 283 500 €
- Участници
- 6
- Схема
- MSCA-RISE
Линиите свързват координатора с партньорите.
Накратко на български
Микрофлуидни чипове се разработват за прецизно подаване на лекарства при пациенти с левкемия чрез компютърни модели. Това помага за оптимизиране на дозите според състоянието на всеки човек и намаляване на страничните ефекти от химиотерапията.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Cost-effective microfluidic electronic devices for optimal drug administration based on fractional pharmacokinetics for leukemia treatments
Worldwide, more than a quarter of a million people are diagnosed with leukaemia each year – including around 75 000 in Europe – accounting for 2.5 % of all cancers. Significantly, the disease accounts for 35 % of all cancers in children up to the age of 14. Though leukaemia treatments have advanced rapidly in recent years, the development of new therapeutic strategies and innovative drug delivery devices is considered essential to increasing long-term survival rates and reducing the debilitating side effects of chemotherapy. The EU-funded MEDLEM project is harnessing advances in nano- and microtechnologies to develop and test a multi-functional and patient-tailored dosing solution for leukaemia patients. The solution involves microfluidic chips – tiny biomedical devices able to accurately control the flow of drugs into the body – and promises to transform treatments for many diseases that require frequent and carefully regulated doses of medication. Building on the experience of each team member, the MEDLEM project aims were to bring new technologies together, to form a comprehensive, integrative, multi-functional and patient-tailored therapy, using cutting-edge techniques and real-time analysis of patients’ well-being and response to medications. The MEDLEM team were focused on two main tasks: firstly, capturing pathology and physiology data in computer models combined with specific data about the health and treatment responses of individual patients in order to test the dynamics of different drug administration procedures, and secondly, to use this data to define an optimal dosing solution implemented via a smart microfluidic device.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The project entitled: “Cost-effective microfluidic electronic devices for optimal drug administration based on fractional pharmacokinetics for leukemia treatments”, with acronym MEDLEM, has a general objective to foster exchanging knowledge and sharing different culture and approaches in reaching high level of excellence, in research and innovation, in the framework of this field.The project is aimed at strengthening research collaboration through active networking, staff exchange and dissemination activities between 4 European organizations from Serbia, Germany and France as well as 2 non-European institutions from Thailand and Australia, in linking the fields of microfluidic electronic devices, optimal drug administration, fractional pharmacokinetics, and leukemia treatments. The project will exploit complementary competencies and synergies of the participants, and enable knowledge sharing via international/inter-sectoral mobility, based on secondments of research staff. The consortium offers a unique opportunity that creativity and entrepreneurship will flourish and will help exchanged personnel to turn creative ideas into innovative electronics products, reaching breakthroughs in modelling, drug administration and improvements in therapy protocols.The main technical goals of the joint research programme are:- Development of fractional pharmacokinetic models and procedures for parameter identification within these models;- Design and fabrication of microfluidic device with in-built electronics for optimal drug delivery protocol;- Pharmacokinetics determination of the pharmaceuticals for leukemia treatments and its testing in vitro and in vivo systems;- Optimal control problem, its numerical solution and implementation.The proposal will develop new research links and strengthen the current research links among the partners and will help build up long-term, world-class research in more successful leukemia treatments.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
- Виж в CORDIS
- DOI: 10.3030/690876
- https://arquivo.pt/wayback/20201229173358/http://www.medlemproject.com/
- https://ec.europa.eu/research-and-innovation/en/projects/success-stories/all/targeting-leukaemia-personalised-treatment
Данни: CORDIS, © Европейски съюз